Hopkins study points to cause of pancreatic cancer immunotherapy resistance

Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds

In a phase Ib/II clinical trial known as EPCORE NHL-2, a team of researchers—led by Joshua Brody, director of the Lymphoma Immunotherapy Program at the Tisch Cancer Institute at Mount Sinai—showed the benefit of combining chemotherapy with immunotherapy for diffuse large B-cell lymphoma. The results were published earlier this month in the journal Blood.

January 31, 2025

Vol.51 No.04

Clinical Roundup

Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data

OS Therapies Inc. announced positive data from a phase IIb clinical trial (NCT04974008) of OST-HER2 (OST31-164)—the company’s HER2-targeted immunotherapy candidate in the rare pediatric-designated indication of prevention of recurrent, fully resected, lung metastatic osteosarcoma.

January 17, 2025

Vol.51 No.02

Drugs & Targets

MAIA Biotechnology, BeiGene announce clinical supply agreement

MAIA Biotechnology Inc. and BeiGene entered into a clinical supply agreement to assess the efficacy of THIO, MAIA Biotechnology’s small molecule telomere-targeting anticancer agent, in combination with BeiGene’s immune checkpoint inhibitor tislelizumab, in three cancer indications. The single-arm pivotal phase II trials will study the drug combination in hepatocellular carcinoma, small cell lung cancer, and colorectal cancer.

January 17, 2025

Vol.51 No.02

Clinical Roundup

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

Researchers from City of Hope, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, the University of Pennsylvania, and NIH have developed a way to add features to T cells to help them overcome mechanisms of chimeric antigen receptor T-cell therapy resistance. The new system is outlined in a paper published in Nature Biomedical Engineering.

January 10, 2025

Vol.51 No.01

Clinical Roundup

Physicians with the Lymphoma Research Foundation present research focused on immunotherapy, disparities at ASH 2024

Several physicians and lymphoma experts who work closely with the Lymphoma Research Foundation presented abstracts at the 66th annual ASH Annual Meeting and Exposition in San Diego, CA on Dec. 7-10, 2024.

January 10, 2025

Vol.51 No.01

Clinical Roundup

UCSD researchers identify enzyme that promotes pancreatic tumor growth and spread

Researchers at University of California San Diego School of Medicine have discovered that an enzyme called MICAL2 promotes tumor growth and spread in pancreatic ductal adenocarcinomas, the most common form of pancreatic cancer.

January 10, 2025

Vol.51 No.01

Hopkins study points to cause of pancreatic cancer immunotherapy resistance

YOU MAY BE INTERESTED IN

Chemo + immunotherapy achieve higher complete remission rates in DLBCL than either treatment alone, Mount Sinai trial finds

Immunotherapy for pediatric osteosarcoma with lung metastases after resection shows positive data

MAIA Biotechnology, BeiGene announce clinical supply agreement

Researchers develop system which helps overcome CAR T-cell resistance in preclinical models

Physicians with the Lymphoma Research Foundation present research focused on immunotherapy, disparities at ASH 2024

UCSD researchers identify enzyme that promotes pancreatic tumor growth and spread

Renew today!

Subscriber content

Never miss an issue!

Login